On May 9, RocketWerkz received an unexpected email from Unity Technologies. Unity's data, the email said, showed that some of the studio's employees had been using personal Unity licenses instead of ...
Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback